The study said a class of drugs called TZDs affect patients to feel hunger in the brain and they tend to eat more than required, increasing their body weight in the process.
“This is important because many people with Type II diabetes are taking anti-diabetics, known as thiazolidinediones (TZDs), which specifically activate these sensors,” said study author Johnny Garretson of the Georgia State University. People taking these TZDs feel hungrier and eat more to gain more weight, Garretson pointed out.
The study found peroxisome proliferator-activated receptor &Upsih (PPAR&Upsih); sensors on hunger-stimulating cells, known as agouti-related protein (AgRP) cells, at the base of the brain in the hypothalamus region that causes the craving for more food.
“When they are taking these drugs, it is activating these receptors, which we believe are controlling feeding through the mechanism that we found,” Garretson noted.
“We discovered that activating these receptors makes our rodent animal model eat more and store more food for later, while blocking these receptors makes them eat less and store less food for later, even after they have been food deprived and they’re at their hungriest,” Garretson said.
The study has been published in the Journal of Neuroscience.
In addition to the TMZs used in anti-diabetic drugs, even emulsifiers, which are added to most processed foods to extend shelf life, are found to promote intestinal inflammation that results in obesity.
In an experiment on mice conducted by the same varsity researchers, it was found that bacterial changes in gut induced by emulsifiers resulted in intestinal inflammation and metabolic syndrome, characterized by increased levels of food consumption, obesity, hyperglycemia and insulin resistance.